Share Name Share Symbol Market Type Share ISIN Share Description
Provexis Plc LSE:PXS London Ordinary Share GB00B0923P27 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 0.825 0.00 01:00:00
Bid Price Offer Price High Price Low Price Open Price
0.75 0.90
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Food Producers 0.35 -0.42 -0.02 18
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 0.825 GBX

Provexis (PXS) Latest News

More Provexis News
Provexis Investors    Provexis Takeover Rumours

Provexis (PXS) Discussions and Chat

Provexis (PXS) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Provexis trades in real-time

Provexis (PXS) Top Chat Posts

Provexis Daily Update: Provexis Plc is listed in the Food Producers sector of the London Stock Exchange with ticker PXS. The last closing price for Provexis was 0.83p.
Provexis Plc has a 4 week average price of 0.75p and a 12 week average price of 0.75p.
The 1 year high share price is 1.40p while the 1 year low share price is currently 0.55p.
There are currently 2,204,154,856 shares in issue and the average daily traded volume is 4,182,358 shares. The market capitalisation of Provexis Plc is £18,184,277.56.
rikid2: I buy it in the Circulease format from Healthspan, frequently on half price offer.
redprince: Huntergis - i read somewhere that it was the thick end of a million although i cannot remember if that was before they increased the number of studies? Yes i agree By-Health were almost certainly consulted about the Chinese distributor. Not at all sure about By-Health buying us out - first they would have to see it being worth their while and second they would have to get 75% of votes to support it. Pxs shares are held by approx 3-4000 people of whom a very small number own an awful lot.The big holders are imo unlikely to sell out until they see the full value of any deal realised.I own over 1% and would not agree to a sale until i could determine what any deal looked like. As for the agm this year...I very much doubt it although I have done on a number of occasions before. Aimho.
huntergls: RP, I think it's more than a million but of course none of us really know. Yes agree blue hat is around a year away. Hence us getting FF+ into the Chinese market. Bi-Health I would imagine been consulted first as I would be p.. off if I was investing a lot of money in this product. If I was bi-health I would already be buying shares in PXS as I am 99% certain they will buy us out as soon as they get blue hat. I am also hoping we will here about fruitflow plus nitrates soon and let's hope one of the big sports makers have been involved in trials. Anything below a penny seems a good buy at the moment. Looking forward to the AGM this year. Will you be going
winner31: Rp no I don’t think it’s anything to do with Pxs , but I’m just pointing out the progress BH who have spent millions getting our products to market have made , they are valued at about £6b now as opposed to £2b when we first partnered with them that can only be good for Pxs . With possibly 9 new products coming to market with a unique substance i’d Be surprised if some serious Chinese investors weren’t at least keeping an eye on Bh .
redprince: winner - you are imho clutching at straws again.By-Health chare price moves up 5% means what exactly?Do you think the Chinese stock market is waiting for Blue Hat approval? By-Health is a susbtantial company and you can be quite certain that Blue Hat which is probably at least another year away will have had nothing whatsoever to do with the rise.
gix er: redprince, are you looking at the same bid / ask as me or the LSE price which is wrong? Just asking as its been a while since I remember the bid closing at (or above)1p. 7% spread is not to shabby for pxs lately.
twodegrees: WHAT IS GOING ON..... Provexis raise 17 December 2020 Placing of new ordinary shares to raise GBP1.0 million provexis, the business that develops, licenses and sells the proprietary, scientifically-proven Fruitflow(R) heart-health functional food ingredient, is pleased to announce it has raised a gross GBP1.0 million via a placing (the 'Placing'), conditional on admission to trading on AIM, of 133,333,349 new ordinary shares of 0.1p each (the 'New Provexis Shares') with new and existing investors. The New Provexis Shares will be issued at a price of 0.75p per share (the 'Placing Price'), and rank pari passu in all respects with the existing ordinary shares of 0.1p each in Provexis. No commissions or expenses will be payable on the issue of the New Provexis Shares. The Placing Price represents a discount of 6.3 per cent. to the closing mid-market price per Ordinary Share on 16 December 2020, being the latest practicable date prior to this announcement. and now they raise 19 February 2021 Provexis plc ('Provexis' or the 'Company') Placing of new ordinary shares to raise GBP50,000 Provexis, the business that develops, licenses and sells the proprietary, scientifically-proven Fruitflow(R) heart-health functional food ingredient, is pleased to announce it has raised a gross GBP50,000 via a placing (the 'Placing'), conditional on admission to trading on AIM, of 6,666,667 new ordinary shares of 0.1p each (the 'New Provexis Shares'). Looks to me that this seems a uselesss way to raise money, why only £50,000, oh and a a director buys a tranch of them.. EXCUSE ME, but seems like this is being done to cover salaries and the shareholders in provexis, who have been here for years and years are seeing the same old cycle of raise money to keep the salaries of a few. Anyone agree with me.... What happened to the £1 million that they raised in Dec 2020, what have they done with it
twodegrees: The only consolation here is that the placing price, year on year is rising....unlike the share price.
winner31: Rich i have always thought that DSM have their own agenda when it comes to ff , of course it would be in their interest to not allow the pxs share price to get ahead of itself with regard to market cap ,we all know what happened 10 years or so ago , does anyone else think it’s strange that some years DSM throw £20 or 30k for marketing and so boosting the revenue of pxs and the the next year nothing , so flattening out any spikes in revenue and so the share price , all looks to me like they will make a bid at some stage but only what they want to pay and no more ,may be 3p which in my opinion way under values the potential of the technology .
winner31: Notable News Buzz: Provexis Plc, (LON: PXS) October 18, 2019 No Comments LON: PXSProvexis Plc On Thursday the Provexis Plc, LON: PXS), the Trending-Graph. Every buying and selling session display one-of-a-kind measures and patterns about PXS stock.Now we observed the Many factors that seen on close of the Previous session. Toward the day’s end, it’s only a stock’s show that issues. Summary Of The Provexis Plc In Stock Exchange LON: The PXS share price closed at 0.38 with the change of 0.03 during the period of last trading session. Trading volume can help an investor to identify the momentum in a stock and confirm a trend. If trading volume raised, prices generally move in a similar direction. That is, if security is proceeding higher in an uptrend, the volume of the protection should also increase and vice versa. The Company’s current volume remained at 3424534.00. It will be even better to share yesterday’s volume of the Company, i.e., 1237316.00. Market Capitalization of Provexis Plc : Market Capitalization is the accurate measure of a company’s value. There’s a common misconception that a company’s each-share stock price holds as much importance as its market capitalization when it comes to picking stocks to buy. This fallacy occurs especially often in the case of new investors. The market capitalization of the Company recorded at PXS. Buy/Sell/Hold Analysis of PXS: Buy Signals: An event or condition that alerts a person to place a purchase order for an investment. Buy signals can be either observed by analyzing chart patterns or calculated by trading systems. Hold Signals: An analyst’s recommendation to neither purchase nor sell a security. A company or organization with a hold recommendation mostly is required to perform with the market or a similar pace as comparable companies.
Provexis share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210624 07:13:32